DAV132-IRT is an orally-administered product designed to preserve the intestinal microbiome from disruptions caused by certain chemotherapies and to reduce their digestive toxicity.
Specifically, DAV132-IRT is being developed to prevent irinotecan-induced late-onset severe diarrhea in patients with pancreatic and colorectal cancer. Similar to DAV132, DAV132-IRT acts in the colon by capturing irinotecan and SN38, its toxic metabolite to reduce its gastrointestinal toxicity and thus increase the safety and efficacy of the treatment.
DAV132-IRT should improve the quality of life of patients and delay any discontinuation or dose reduction of chemotherapy that would reduce the patient’s chances of survival.
Mechanism of action of DAV132-IRT
- When a patient is treated with irinotecan, active metabolites of irinotecan reach the colon and create direct damage to the intestinal cells, leading to inflammation of the colon and a state of dysbiosis of the intestinal microbiome. This causes severe diarrhea (grade ≥ 3) in these patients, which may lead to a reduction in the dose of irinotecan administered, or even to discontinuation of treatment. This can have a very important impact on the quality of life but also on the survival of patients, whose cancer is treated with less efficiency.
By irreversibly capturing the active residues of irinotecan in the colon, DAV132-IRT reduces the incidence and severity of severe diarrhea in patients without affecting the antitumor efficacy of their chemotherapy. Thus, chemotherapy can be given at its optimal dose and is not interrupted prematurely, increasing patients’ chances of survival.
Why is DAV132-IRT unique?
DAV132-IRT addresses an important unmet medical need: metastatic pancreatic adenocarcinoma is currently considered incurable and the average life expectancy of patients is estimated to be between 7 and 11 months. In this patient population, any new treatment that improves quality of life and survival will have a strong impact on patient management. DAV132-IRT would therefore provide a strong clinical benefit for this patient population.